Belite Bio Announces Uplisting to the Nasdaq Global Select MarketGlobeNewsWire · Oct 19, 2026
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1GlobeNewsWire · Oct 14, 2026
Belite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesGlobeNewsWire · Oct 1, 2026
Belite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesGlobeNewsWire · Sep 28, 2026
Belite Bio, Inc. Sponsored ADR $BLTE Shares Sold by Squarepoint Ops LLCDefense World · Sep 17, 2026
Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 14, 2026Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.73 | -$0.70 | Beat |
| May 20, 2026 | -$0.60 | -$0.34 | Beat |
| Mar 2, 2026 | -$0.56 | -$0.38 | Beat |
| Nov 10, 2025 | -$0.53 | -$0.65 | Miss |
| Aug 11, 2025 | -$0.47 | -$0.50 | Miss |
| May 13, 2025 | -$0.36 | -$0.45 | Miss |